3vow
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
+ | |||
==Crystal Structure of the Human APOBEC3C having HIV-1 Vif-binding Interface== | ==Crystal Structure of the Human APOBEC3C having HIV-1 Vif-binding Interface== | ||
<StructureSection load='3vow' size='340' side='right' caption='[[3vow]], [[Resolution|resolution]] 2.15Å' scene=''> | <StructureSection load='3vow' size='340' side='right' caption='[[3vow]], [[Resolution|resolution]] 2.15Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[3vow]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[3vow]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3VOW OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3VOW FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">APOBEC3C, APOBEC1L, PBI ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">APOBEC3C, APOBEC1L, PBI ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3vow FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vow OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3vow RCSB], [http://www.ebi.ac.uk/pdbsum/3vow PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3vow FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3vow OCA], [http://pdbe.org/3vow PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3vow RCSB], [http://www.ebi.ac.uk/pdbsum/3vow PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3vow ProSAT]</span></td></tr> |
</table> | </table> | ||
+ | == Function == | ||
+ | [[http://www.uniprot.org/uniprot/ABC3C_HUMAN ABC3C_HUMAN]] DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single-or double-stranded RNA. Exhibits antiviral activity against simian immunodeficiency virus (SIV), hepatitis B virus (HBV), herpes simplex virus 1 (HHV-1) and Epstein-Barr virus (EBV) and may inhibit the mobility of LTR and non-LTR retrotransposons. May also play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation.<ref>PMID:12859895</ref> <ref>PMID:15466872</ref> <ref>PMID:16527742</ref> <ref>PMID:20062055</ref> <ref>PMID:21496894</ref> <ref>PMID:21632763</ref> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 15: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
+ | <div class="pdbe-citations 3vow" style="background-color:#fffaf0;"></div> | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Human]] |
[[Category: Iwatani, Y]] | [[Category: Iwatani, Y]] | ||
[[Category: Kitamura, S]] | [[Category: Kitamura, S]] |
Revision as of 15:30, 11 August 2016
Crystal Structure of the Human APOBEC3C having HIV-1 Vif-binding Interface
|
Categories: Human | Iwatani, Y | Kitamura, S | Suzuki, A | Watanabe, N | Antiviral deffense | Apobec3 | Apobec3c | Bet | Hiv | Hiv-1 vif | Host-virus interaction | Hydrolase | Metal-binding | Single domain | Sivagm | Z2